Arcutis Biotherapeutics IncARQT

ARQT current price
$12.25+420.08%

Capital at risk.

1W
-3.01%
1M
+17.00%
3M
+24.90%
6M
+59.42%
1Y
+420.08%
MAX
-41.79%
About Arcutis Biotherapeutics Inc
Ticker
info
ARQT
Trading on
info
NASDAQ
ISIN
info
US03969K1088
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Todd Franklin Watanabe M.A.
Headquarters
info
3027 Townsgate Road, Westlake Village, CA, United States, 91361
Employees
info
296
Website
info
arcutis.com
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Metrics
BasicAdvanced
Market cap
info
$1.49B
P/E ratio
info
-
EPS
info
-$1.67
Dividend Yield
info
0.00%
Beta
info
1.19
Forward P/E ratio
info
0
EBIDTA
info
$-179M
Ex dividend date
info
-
Price & volume
Market cap
info
$1.49B
Average daily volume
info
1.9M
90-day return
info
24.90%
30-day return
info
17.00%
7-day return
info
-3.01%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
10.78
Price to book
info
9.15
Earnings
EPS
info
-$1.67
EPS estimate (current quarter)
info
-$0.42
EPS estimate (next quarter)
info
-$0.36
EBITDA
info
$-179M
Revenues (TTM)
info
$139M
Revenues per share (TTM)
info
$1.23
Technicals
Beta
info
1.19
52-week High
info
$13.50
52-week Low
info
$2.28
50-day moving average
info
$10.17
200-day moving average
info
$9.74
Short ratio
info
10.26
Short %
info
24.87%
Management effectiveness
ROE (TTM)
info
192.31%
ROA (TTM)
info
31.14%
Profit margin
info
140.97%
Gross profit margin
info
$2.9M
Operating margin
info
87.29%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
17.40%
Share stats
Outstanding Shares
info
117M
Float
info
85.8M
Insiders %
info
2.15%
Institutions %
info
113.61%
Analyst Insights & forecasts
info

86% Buy

14% Hold

0% Sell

Based on information from 7 analysts.

Average price target

info
$19.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.72
-$0.77
6.49%
Q4 • 23Beat
-$0.32
-$0.73
56.16%
Q1 • 24Beat
-$0.42
-$0.52
19.23%
Q2 • 24Beat
-$0.33
-$0.42
21.43%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$30.9M
$-52.3M
169.59%
Q2 • 24
$44.8M
$-41.5M
92.81%
Q3 • 24
45.04%
20.63%
45.27%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$445M
$258M
58.08%
Q2 • 24
$437M
$281M
64.18%
Q3 • 24
1.66%
8.66%
10.50%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-45.1M
$-62.1M
$1.5M
$-45.1M
Q2 • 24
$-34.7M
$84.8M
$0.4M
$-34.8M
Q3 • 24
23.12%
236.44%
72.92%
22.80%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Extreme greed

+1.5

0.94

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Arcutis Biotherapeutics Inc share?
Collapse

Arcutis Biotherapeutics Inc shares are currently traded for $12.25 per share.

How many shares does Arcutis Biotherapeutics Inc have?
Collapse

Arcutis Biotherapeutics Inc currently has 117M shares.

Does Arcutis Biotherapeutics Inc pay dividends?
Collapse

No, Arcutis Biotherapeutics Inc doesn't pay dividends.

What is Arcutis Biotherapeutics Inc 52 week high?
Collapse

Arcutis Biotherapeutics Inc 52 week high is $13.50.

What is Arcutis Biotherapeutics Inc 52 week low?
Collapse

Arcutis Biotherapeutics Inc 52 week low is $2.28.

What is the 200-day moving average of Arcutis Biotherapeutics Inc?
Collapse

Arcutis Biotherapeutics Inc 200-day moving average is $9.74.

Who is Arcutis Biotherapeutics Inc CEO?
Collapse

The CEO of Arcutis Biotherapeutics Inc is Todd Franklin Watanabe M.A..

How many employees Arcutis Biotherapeutics Inc has?
Collapse

Arcutis Biotherapeutics Inc has 296 employees.

What is the market cap of Arcutis Biotherapeutics Inc?
Collapse

The market cap of Arcutis Biotherapeutics Inc is $1.49B.

What is the P/E of Arcutis Biotherapeutics Inc?
Collapse

The current P/E of Arcutis Biotherapeutics Inc is null.

What is the EPS of Arcutis Biotherapeutics Inc?
Collapse

The EPS of Arcutis Biotherapeutics Inc is -$1.67.

What is the PEG Ratio of Arcutis Biotherapeutics Inc?
Collapse

The PEG Ration of Arcutis Biotherapeutics Inc is null.

What do analysts say about Arcutis Biotherapeutics Inc?
Collapse

According to the analysts Arcutis Biotherapeutics Inc is considered a buy.

Arcutis Biotherapeutics Inc news